News

Roche’s ALK inhibitor Alecensa receives FDA approval to treat early-stage NSCLC

Apr 19, 2024 | Regulatory, News

Approximately half of all patients with early lung cancer experience cancer recurrence following surgery

Ipsen announces launch of new UK headquarters in London life sciences community

Apr 19, 2024 | News, Research

The Paddington site will serve as one of the company’s three global hubs

GSK’s shingles vaccine shown to maintain high protection in long-term study

Apr 19, 2024 | News, Research

The infectious condition affects up to one in three people globally in their lifetimes

UK scientists discover two genes offering potential drug targets against skin cancer

Apr 19, 2024 | News, Research

The three major types of skin cancer are basal cell carcinoma, squamous cell carcinoma and melanoma

Takeda gains rights to Kumquat’s immune-oncology programme in deal worth over $1.2bn

Apr 18, 2024 | News, Sales

The selected candidate can be developed as a monotherapy, combination therapy or both

Roche reveals promising phase 3 results for subcutaneous Ocrevus in progressive and relapsing MS

Apr 18, 2024 | News, Research

The chronic neurological condition affects more than 2.8 million people worldwide

Novartis presents positive long-term data for relapsing MS treatment Kesimpta

Apr 18, 2024 | News, Research

Approximately 85% of MS patients are initially diagnosed with relapsing forms of the neurological disease

UK scientists reveal promising new treatment strategy for acute myeloid leukaemia

Apr 18, 2024 | News, Research

The aggressive form of blood cancer is responsible for more than 3,000 new cases in the UK every year

AstraZeneca study reveals increasing number of people impacted by chronic kidney disease

Apr 18, 2024 | News, Research

CKD is a progressive condition that affects nearly 850 million people worldwide

Roche receives FDA breakthrough device designation for Alzheimer’s disease blood test

Apr 17, 2024 | News, Regulatory

Around 55 million people globally are living with dementia, which is estimated to rise to 139 million by 2050

Sanofi presents promising results for investigational frexalimab in relapsing forms of MS

Apr 17, 2024 | News, Research

Approximately 85% of patients are initially diagnosed with relapsing forms of the neurological disease

Novartis shares positive late-stage results for Fabhalta in rare kidney disease IgA nephropathy

Apr 17, 2024 | News, Research

Approximately 25 people per million worldwide are diagnosed with IgAN every year

Roche’s ALK inhibitor Alecensa receives FDA approval to treat early-stage NSCLC

Ipsen announces launch of new UK headquarters in London life sciences community

GSK’s shingles vaccine shown to maintain high protection in long-term study

UK scientists discover two genes offering potential drug targets against skin cancer

Takeda gains rights to Kumquat’s immune-oncology programme in deal worth over $1.2bn

Roche reveals promising phase 3 results for subcutaneous Ocrevus in progressive and relapsing MS

Novartis presents positive long-term data for relapsing MS treatment Kesimpta

UK scientists reveal promising new treatment strategy for acute myeloid leukaemia

AstraZeneca study reveals increasing number of people impacted by chronic kidney disease

Roche receives FDA breakthrough device designation for Alzheimer’s disease blood test

Sanofi presents promising results for investigational frexalimab in relapsing forms of MS

Novartis shares positive late-stage results for Fabhalta in rare kidney disease IgA nephropathy

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links